163 related articles for article (PubMed ID: 38178222)
21. Enhancing the Thermostability and Immunogenicity of a Respiratory Syncytial Virus (RSV) Live-Attenuated Vaccine by Incorporating Unique RSV Line19F Protein Residues.
Rostad CA; Stobart CC; Todd SO; Molina SA; Lee S; Blanco JCG; Moore ML
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263264
[TBL] [Abstract][Full Text] [Related]
22. Virus-like Particle Vaccine Expressing the Respiratory Syncytial Virus Pre-Fusion and G Proteins Confers Protection against RSV Challenge Infection.
Lee SH; Chu KB; Kim MJ; Mao J; Eom GD; Yoon KW; Ahmed MA; Quan FS
Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986643
[TBL] [Abstract][Full Text] [Related]
23. An RSV Live-Attenuated Vaccine Candidate Lacking G Protein Mucin Domains Is Attenuated, Immunogenic, and Effective in Preventing RSV in BALB/c Mice.
Roe MK; Perez MA; Hsiao HM; Lapp SA; Sun HY; Jadhao S; Young AR; Batista YS; Reed RC; Taz A; Piantadosi A; Chen X; Liang B; Koval M; Snider TA; Moore ML; Anderson EJ; Anderson LJ; Stobart CC; Rostad CA
J Infect Dis; 2022 Dec; 227(1):50-60. PubMed ID: 36281651
[TBL] [Abstract][Full Text] [Related]
24. Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice.
Luo J; Qin H; Lei L; Lou W; Li R; Pan Z
Front Immunol; 2022; 13():1054005. PubMed ID: 36578490
[TBL] [Abstract][Full Text] [Related]
25. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.
Murawski MR; McGinnes LW; Finberg RW; Kurt-Jones EA; Massare MJ; Smith G; Heaton PM; Fraire AE; Morrison TG
J Virol; 2010 Jan; 84(2):1110-23. PubMed ID: 19889768
[TBL] [Abstract][Full Text] [Related]
26. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.
Quan FS; Kim Y; Lee S; Yi H; Kang SM; Bozja J; Moore ML; Compans RW
J Infect Dis; 2011 Oct; 204(7):987-95. PubMed ID: 21881112
[TBL] [Abstract][Full Text] [Related]
27. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
[TBL] [Abstract][Full Text] [Related]
28. Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.
Lee Y; Lee YT; Ko EJ; Kim KH; Hwang HS; Park S; Kwon YM; Kang SM
Hum Vaccin Immunother; 2017 Nov; 13(11):2594-2605. PubMed ID: 28854003
[TBL] [Abstract][Full Text] [Related]
29. Construction and immunological evaluation of hepatitis B virus core virus-like particles containing multiple antigenic peptides of respiratory syncytial virus.
Lei L; Qin H; Luo J; Tan Y; Yang J; Pan Z
Virus Res; 2021 Jun; 298():198410. PubMed ID: 33819519
[TBL] [Abstract][Full Text] [Related]
30. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
[TBL] [Abstract][Full Text] [Related]
31. A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.
Boyoglu-Barnum S; Gaston KA; Todd SO; Boyoglu C; Chirkova T; Barnum TR; Jorquera P; Haynes LM; Tripp RA; Moore ML; Anderson LJ
J Virol; 2013 Oct; 87(20):10955-67. PubMed ID: 23885067
[TBL] [Abstract][Full Text] [Related]
32. Two RSV Platforms for G, F, or G+F Proteins VLPs.
Ha B; Yang JE; Chen X; Jadhao SJ; Wright ER; Anderson LJ
Viruses; 2020 Aug; 12(9):. PubMed ID: 32824936
[TBL] [Abstract][Full Text] [Related]
33. Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.
Kwon YM; Lee Y; Kim KH; Jung YJ; Li Z; Jeeva S; Lee S; Moore ML; Kang SM
Vaccine; 2019 Oct; 37(44):6656-6664. PubMed ID: 31542260
[TBL] [Abstract][Full Text] [Related]
34. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
[TBL] [Abstract][Full Text] [Related]
35. Prior respiratory syncytial virus infection reduces vaccine-mediated Th2-skewed immunity, but retains enhanced RSV F-specific CD8 T cell responses elicited by a Th1-skewing vaccine formulation.
Eichinger KM; Kosanovich JL; Perkins TN; Oury TD; Petrovsky N; Marshall CP; Yondola MA; Empey KM
Front Immunol; 2022; 13():1025341. PubMed ID: 36268035
[TBL] [Abstract][Full Text] [Related]
36. Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.
McGinnes Cullen L; Schmidt MR; Kenward SA; Woodland RT; Morrison TG
J Virol; 2015 Jul; 89(13):6835-47. PubMed ID: 25903340
[TBL] [Abstract][Full Text] [Related]
37. Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity.
Huang JM; Wang SY; Lai MR; Tseng YK; Chi YH; Huang LM
Vaccine; 2021 Jun; 39(24):3259-3269. PubMed ID: 33972124
[TBL] [Abstract][Full Text] [Related]
38. Recombinant baculovirus-based vaccine expressing M2 protein induces protective CD8
Lee JY; Chang J
J Microbiol; 2017 Nov; 55(11):900-908. PubMed ID: 29076066
[TBL] [Abstract][Full Text] [Related]
39. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
40. The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV.
Cullen LM; Schmidt MR; Morrison TG
Hum Vaccin Immunother; 2017 Dec; 13(12):2814-2823. PubMed ID: 28604155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
